OverviewRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.The Opportunity: As part of our expanding European organization, we seek a strategic and hands-on Senior Director, Regulatory Affairs, Europe who will play a critical role in leading and executing the regional regulatory strategy for our portfolio across the EU, EEA, UK and Switzerland. The Senior Director will serve as a strategic partner to Global Regulatory Teams, ensuring alignment of the European regulatory strategy with the global and regional company’s objectives. They will independently represent regulatory affairs in global and regional cross-functional teams and provide targeted, strategic expertise of one or more therapeutic areas for oncology programs across the Global and European organization. The Senior Director will lead the Regional Regulatory Affairs Team, foster the career development of direct reports and contribute to departmental leadership activities. The candidate must have a thorough understanding of oncology drug development, applicable European regulations and is responsible for driving proactive engagement with health authorities including the EMA/MHRA/Swissmedic ensuring successful regulatory outcomes. The role will report to the VP, Head of Regulatory Affairs, Europe.
#J-18808-Ljbffr